Rituximab | EPFL Graph Search

Are you an EPFL student looking for a semester project?

Work with us on data science and visualisation projects, and deploy your project as an app on top of GraphSearch.

Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia (in non-geriatric patients), rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow injection into a vein. Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza (F.K.A. Tuxella), Rixathon, Ruxience, and Truxima. Common side effects which often occur within two hours of the medication being given include rash, itchiness, low blood pressure, and shortness of breath. Infections are also common. Severe side effects include reactivation of hepatitis B in those previously infected, progressive multifocal leukoencephalopathy, toxic epidermal necrolysis, and death. It is unclear if use during pregnancy is safe for the developing fetus or newborn baby, but it is not proven harmful. Rituximab is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B cells. When it binds to this protein it triggers cell death. Rituximab was approved for medical use in 1997. It is on the World Health Organization's List of Essential Medicines. Rituximab is co-marketed by Biogen and Genentech in the U.S., by Hoffmann-La Roche in Canada and the European Union, Chugai Pharmaceuticals, Zenyaku Kogyo in Japan and AryoGen in Iran. Rituximab is a chimeric monoclonal antibody targeted against CD20 which is a surface antigen present on B cells. Therefore, it acts by depleting normal as well as pathogenic B cells while sparing plasma cells and hematopoietic stem cells as they do not express the CD20 surface antigen.

About this result

This page is automatically generated and may contain information that is not correct, complete, up-to-date, or relevant to your search query. The same applies to every other page on this website. Please make sure to verify the information with EPFL's official sources.

Related concepts (45)

Related courses (2)

Related lectures (3)

Plasmapheresis

Plasmapheresis (from the Greek πλάσμα, plasma, something molded, and ἀφαίρεσις aphairesis, taking away) is the removal, treatment, and return or exchange of blood plasma or components thereof from and to the blood circulation. It is thus an extracorporeal therapy, a medical procedure performed outside the body. Three general types of plasmapheresis can be distinguished: Autologuous, removing blood plasma, treating it in some way, and returning it to the same person, as a therapy.

Rituximab

Diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a cancer of B cells, a type of lymphocyte that is responsible for producing antibodies. It is the most common form of non-Hodgkin lymphoma among adults, with an annual incidence of 7–8 cases per 100,000 people per year in the US and UK. This cancer occurs primarily in older individuals, with a median age of diagnosis at ~70 years, although it can occur in young adults and, in rare cases, children. DLBCL can arise in virtually any part of the body and, depending on various factors, is often a very aggressive malignancy.

ChE-436: Pharmaceutical biotechnology

The course focuses on the development and application of biotechnology-based approaches to human diseases. It provides current information on the engineering and pharmaceutical production of highly sp

CH-317: Drug discovery and development

This course discusses the molecular basis of diseases and how drugs work. Concepts and processes employed in today's drug discovery and development are covered. The first part of the course focuses on

Antibodies: Basics and Early Development CH-317: Drug discovery and development

Explores the basics and early development of antibodies, including their structure, function, diversity, and application in diseases.

Antibodies: Technologies and Therapeutics CH-317: Drug discovery and development

Explores the development and challenges of antibody-based therapeutics, including chimeric and humanized antibodies, alternative scaffolds, and in vitro selection.

Kidney-on-a-Chip Technologies MICRO-568: Seminar in physiology and instrumentation

Covers the state-of-the-art kidney-on-chip technologies aiming to facilitate pharmaceutical research and eliminate animal testing.